Cargando…
Progress in medicinal chemistry. Volume 53 /
Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide ran...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Elsevier,
2014.
|
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn870863869 | ||
| 003 | OCoLC | ||
| 005 | 20231120111524.0 | ||
| 006 | m o d | ||
| 007 | cr bn|nnnaucun | ||
| 008 | 140220s2014 ne o 001 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d N$T |d YDXCP |d OCLCF |d OCLCQ |d D6H |d OTZ |d AU@ |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO | ||
| 020 | |a 9780444633958 |q (electronic bk.) | ||
| 020 | |a 0444633952 |q (electronic bk.) | ||
| 020 | |a 9780444633804 |q (electronic bk.) | ||
| 020 | |a 0444633804 |q (electronic bk.) | ||
| 035 | |a (OCoLC)870863869 | ||
| 050 | 4 | |a RS403 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.19 |2 23 |
| 245 | 0 | 0 | |a Progress in medicinal chemistry. |n Volume 53 / |c edited by G. Lawton and D.R. Witty. |
| 264 | 1 | |a Amsterdam : |b Elsevier, |c 2014. | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 500 | |a Includes index. | ||
| 520 | |a Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems, including g-secretase modulators, P2X7 antagonists as therapeutic agents for CNS disorders, N-type calcium channel modulators for the treatment of pain, and more. One of the most respected sources of current medicinal chemistry information. Useful to a broad cross-section of professionals, including chemists, biologists, doctors, and pharmacists. | ||
| 588 | 0 | |a Online resource; title from PDF title page (ScienceDirect, viewed February 20, 2014). | |
| 505 | 0 | |a Front Cover; Progress in Medicinal Chemistry; Copyright; Preface; Contents; Contributors; Chapter One: Structure-Based Drug Design for G Protein-Coupled Receptors; 1. Introduction; 2. Structural Architecture of GPCRs; 3. GPCR Protein-Ligand X-Ray Structures; 4. Mechanisms of Activation: Agonist Bound Structures; 5. Biased Agonism; 6. Traditional Approaches to GPCR Drug Discovery and the Need for Change; 7. Potential of SBDD and FBDD for GPCR Drug Discovery; 7.1. Beta Adrenergic Receptors; 7.2. Histamine Receptor; 7.3. Adenosine Receptors; 7.4. CXCR4 Receptor; 7.5. CRF1 Receptor. | |
| 505 | 8 | |a 8. Conclusions and OutlookAcknowledgments; References; Chapter Two: P2X7 Antagonists as Potential Therapeutic Agents for the Treatment of CNS Disorders; 1. Introduction; 2. P2X7 in the CNS; 2.1. Neuropsychiatric Disorders; 2.2. Neurodegenerative Disorders; 2.3. Pain; 3. P2X7 Modulators in Clinical Trials; 4. P2X7 Receptor Antagonists; 4.1. Monocyclic Hetero and Carbocyclic Antagonists; 4.2. Heteroaromatic-Fused Core Antagonists; 4.3. P2X7 Antagonists in Animal Models of the CNS; 5. Conclusion; References; Chapter Three: �-Secretase Modulators: Current Status and Future Directions. | |
| 505 | 8 | |a 1. Introduction1.1. Alzheimers Disease; 1.2. �-Secretase Biology; 2. GSMs: Chemical Classes; 2.1. Acid Derivatives; 2.1.1. Myriad and Chiesi; 2.1.2. Janssen; 2.1.3. EnVivo; 2.1.4. GSK; 2.1.5. Merck; 2.1.6. Biogen Idec; 2.1.7. Pfizer/Astellas; 2.1.8. Summary; 2.2. Imidazoles and Related Analogues; 2.2.1. TorreyPines; 2.2.2. GSK; 2.2.3. Roche; 2.2.4. Janssen; 2.2.5. BMS; 2.2.6. Pfizer; 2.2.7. Merck; 2.2.8. AstraZeneca; 2.2.9. Boehringer Ingelheim; 2.2.10. Shionogi; 2.2.11. Dainippon Sumitomo; 2.2.12. Summary; 2.3. Natural Products; 3. Chemical Biology; 4. Outlook; 5. Clinical Studies. | |
| 505 | 8 | |a 6. ConclusionsReferences; Chapter Four: Recent Progress in the Discovery and Development of N-Type Calcium Channel Modulators for the Treatment of Pain; 1. Introduction; 2. Voltage-Gated Calcium Channels; 2.1. Cav Channel Architecture; 2.2. Cav Channel Physiology; 2.3. Cav Channel States; 2.4. Implications for Therapeutic Intervention; 3. N-Type Calcium Channels; 3.1. N-Type Biology; 3.2. N-Type Physiology; 3.3. Role in the Pathophysiology of Pain; 4. N-Type Clinical Landscape and Emerging Pipeline; 4.1. Peptide-Derived Therapeutics; 4.1.1. N-Type Blockade by Venom Toxins. | |
| 505 | 8 | |a 4.1.2. Peptide-Derived Therapeutics4.1.3. Peptide Mimetics; 4.2. Small Molecule N-Type Blockers; 4.2.1. Non-Selective Calcium Channel Blockers as a Starting Point; 4.2.2. Piperazine-Based Structures; 4.2.3. Piperidine-Containing Structures; 4.2.4. Indoles and Oxindoles; 4.2.5. Other Approaches; 4.3. N-Type Calcium Channel Modulators in the Clinic; 4.3.1. Z160; 4.3.2. CNV2197944; 5. Concluding Remarks; References; Subject Index; Cumulative Index of Authors for Volumes 1-53; Cumulative Index of Subjects for Volumes 1-53. | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 2 | |a Chemistry, Pharmaceutical |0 (DNLM)D002626 | |
| 650 | 6 | |a Chimie pharmaceutique. |0 (CaQQLa)201-0028674 | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast |0 (OCoLC)fst01060115 | |
| 700 | 1 | |a Lawton, G., |e editor. | |
| 700 | 1 | |a Witty, D. R., |e editor. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780444633804 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/00796468/53 |z Texto completo |